drugset / Trial / NCT01376700

Early Prophylaxis Immunologic Challenge (EPIC) Study

NCT01376700

NaSingle-groupOpen-labelPrevention

Summary

The purpose of the study was to assess if a once-weekly prophylactic regimen of 25 IU/kg ADVATE started at or before 1 year of age and before the onset of a severe bleeding phenotype (ie, joint bleeding), together with the minimization of immunological danger signals, can reduce the incidence rate of inhibitor formation in PUPs with severe and moderately severe hemophilia A.

Timeline

Start
2011-08-26
Primary completion
2012-11-16
Completion
2012-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject ADVATE Protein / enzyme biologic 25 iu/kg Intravenous

Indications